# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
JMP Securities analyst Jonathan Wolleben reiterates Allakos (NASDAQ:ALLK) with a Market Outperform and maintains $3 price ta...
Cantor Fitzgerald analyst Jennifer Kim reiterates Allakos (NASDAQ:ALLK) with a Neutral.
Allakos (NASDAQ:ALLK) reported quarterly losses of $(0.81) per share which missed the analyst consensus estimate of $(0.44) by ...
Allakos (NASDAQ:ALLK) reported quarterly losses of $(0.71) per share which missed the analyst consensus estimate of $(0.47) by ...
Atopic dermatitis and prurigo nodularis skin lesions show evidence of MRGPRX2 mast cell activation and activated macrophages ...